Innovent-Lilly Verzenios China Commercialization | Lucid Diligence Brief
Innovent takes mainland China commercial responsibility for Verzenios as Lilly…
LabGenius and LG Chem Advance Multispecific Antibody Partnership | Lucid Diligence Brief
LabGenius expands validation of its EVA antibody-discovery platform through a…
Lonza Antharis Dual-Payload ADC License | Lucid Diligence Brief
Lonza and Antharis license dual-payload ADC technology for gastrointestinal…
GSK Acquires Nuvalent to Expand Oncology Pipeline | Lucid Diligence Brief
GSK strengthens its oncology portfolio with Nuvalent acquisition, adding…
Nurix Roche Bexobrutideg Deal | Lucid Diligence Brief
Roche’s collaboration with Nurix turns bexobrutideg into a multi-indication BTK…
Public Health Today—June 5, 2026
This weekly update in Public Health highlights major developments across…
Stipple Bio’s Lonza ADC Deal | Lucid Diligence Brief
Stipple Bio’s Lonza ADC license raises the execution test for STP-100 and…
IDEAYA and Roche Collaboration | Lucid Diligence Brief
IDEAYA and Roche Test IDE892 plus RG6505 in MTAP-Deleted RAS-Mutant PDAC…
Rallybio Avenzo Merger and $215M Financing | Lucid Diligence Brief
Rallybio and Avenzo’s reverse merger puts Nasdaq access, $215M financing and…
Pfizer Innovent Oncology Deal | Lucid Diligence Brief
Pfizer Innovent Oncology Deal tests China-originated ADC and multi-specific…
Lucid Diligence Brief: Olema OP-3136 and Bayer Darolutamide Deal
Lucid Diligence Brief: Olema expands OP-3136 into metastatic…
Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay
Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay Raises SERENA-6…